Nucleosome in patients with systemic sclerosis: Possible association with immunological abnormalities via abnormal activation of T and B cells

Annals of the Rheumatic Diseases

Volumn 75, Issue 10, 2016, Pages 1858-1865

  Yoshizaki, Ayumi ^a   Taniguchi, Takashi ^a   Saigusa, Ryosuke ^a   Fukasawa, Takemichi ^a   Ebata, Satoshi ^a   Numajiri, Hiroko ^a   Nakamura, Kouki ^a   Yamashita, Takashi ^a   Takahashi, Takehiro ^a   Toyama, Tetsuo ^a   Asano, Yoshihide ^a   Tedder, Thomas F ^b   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Autoimmunity; B cells; Cytokines; Systemic Sclerosis; T Cells

Indexed keywords

BLEOMYCIN; IMMUNOGLOBULIN G; INTERLEUKIN 17; INTERLEUKIN 4; NUCLEOSOME; TOLL LIKE RECEPTOR 9;

ANIMAL; B LYMPHOCYTE; BLOOD; CASE CONTROL STUDY; CHEMICALLY INDUCED; DISEASE MODEL; FEMALE; HUMAN; IMMUNOLOGY; LONGITUDINAL STUDY; MALE; METABOLISM; MOUSE; NUCLEOSOME; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS; T LYMPHOCYTE;

ANIMALS; B-LYMPHOCYTES; BLEOMYCIN; CASE-CONTROL STUDIES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-17; INTERLEUKIN-4; LONGITUDINAL STUDIES; MALE; MICE; NUCLEOSOMES; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 9;

EID: 85021858511     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207405     Document Type: Article

References (50)

1. Sato S, Hayakawa I, Hasegawa M, et al. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 2003; 120: 542-7.
2. Kurasawa K, Hirose K, Sano H, et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000; 43: 2455-63.
3. Yoshizaki A, Yanaba K, Iwata Y, et al. Elevated serum interleukin-27 levels in patients with systemic sclerosis: association with T cell, B cell and fibroblast activation. Ann Rheum Dis 2011; 70: 194-200.
4. Arnett FC. Is scleroderma an autoantibody mediated disease? Curr Opin Rheumatol 2006; 18: 579-81.
5. Yoshizaki A, Iwata Y, Komura K, et al. Clinical significance of serum hyaluronan levels in systemic sclerosis: association with disease severity. J Rheumatol 2008; 35: 1825-9.
6. Yoshizaki A, Iwata Y, Komura K, et al. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 2008; 172: 1650-63.
7. Yoshizaki A, Komura K, Iwata Y, et al. Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J Clin Immunol 2009; 29: 180-9.
8. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006; 6: 823-35.
9. Luger K, Mäder AW, Richmond RK, et al. Crystal structure of the nucleosome core particle at 2. 8 A resolution. Nature 1997; 389: 251-60.
10. Kornberg RD, Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 1999; 98: 285-94.
11. Holdenrieder S, Stieber P, Bodenmüller H, et al. Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer 2001; 95: 114-20.
12. Lichtenstein AV, Melkonyan HS, Tomei LD, et al. Circulating nucleic acids and apoptosis. Ann N Y Acad Sci 2001; 945: 239-49.
13. van Nieuwenhuijze AE, van Lopik T, Smeenk RJ, et al. Time between onset of apoptosis and release of nucleosomes from apoptotic cells: putative implications for systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 10-14.
14. Zeerleder S, Zwart B, Wuillemin WA, et al. Elevated nucleosome levels in systemic inflammation and sepsis. Crit Care Med 2003; 31: 1947-51.
15. Holdenrieder S, Eichhorn P, Beuers U, et al. Nucleosomal DNA fragments in autoimmune diseases. Ann N Y Acad Sci 2006; 1075: 318-27.
16. Gowda NM, Wu X, Gowda DC. The nucleosome (histone-DNA complex) is the TLR9-specific immunostimulatory component of Plasmodium falciparum that activates DCs. PLoS ONE 2011; 6: e20398.
17. Lartigue A, Courville P, Auquit I, et al. Role of TLR9 in anti-nucleosome and anti-DNA antibody production in lpr mutation-induced murine lupus. J Immunol 2006; 177: 1349-54.
18. [No authors listed]. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-90.
19. LeRoy EC, Black C, Fleischmajer R, Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
20. Sato S, Ihn H, Kikuchi K, et al. Antihistone antibodies in systemic sclerosis: association with pulmonary fibrosis. Arthritis Rheum 1994; 37: 391-4.
21. Steen VD, Powell DL, Medsger TAJ. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31: 196-203.
22. Komura K, Sato S, Hasegawa M, et al. Elevated circulating CD40L concentrations in patients with systemic sclerosis. J Rheumatol 2004; 31: 514-19.
23. Clements PJ, Lachenbruch PA, Seibold JR, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993; 20: 1892-6.
24. Engel P, Zhou L-J, Ord DC, et al. Abnormal B lymphocyte development, activation and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 1995; 3: 39-50.
25. Yoshizaki A, Yanaba K, Iwata Y, et al. Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. J Immunol 2010; 185: 2502-15.
26. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988; 41: 467-70.
27. Yoshizaki A, Yanaba K, Ogawa A, et al. The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin-induced and tight skin mouse models of systemic sclerosis. Arthritis Rheum 2011; 63: 3086-97.
28. Georgescu L, Vakkalanka RK, Elkon KB, et al. Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand. J Clin Invest 1997; 100: 2622-33.
29. Courtney PA, Crockard AD, Williamson K, et al. Lymphocyte apoptosis in systemic lupus erythematosus: relationships with Fas expression, serum soluble Fas and disease activity. Lupus 1999; 8: 508-13.
30. Yoshizaki A, Yanaba K, Ogawa A, et al. Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthritis Rheum 2011; 63: 3575-85.
31. Anders HJ. A Toll for lupus. Lupus 2005; 14: 417-22.
32. Lenert PS. Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus. Arthritis Res Ther 2006; 8: 203.
33. Yanaba K, Bouaziz JD, Matsushita T, et al. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol 2009; 182: 7459-72.
34. Iwata Y, Matsushita T, Horikawa M, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011; 117: 530-41.
35. Alikhan MA, Summers SA, Gan PY, et al. Endogenous Toll-Like Receptor 9 Regulates AKI by Promoting Regulatory T Cell Recruitment. J Am Soc Nephrol 2015. [epub ahead of print 2015].
36. Dibra D, Cutrera JJ, Li S. Coordination between TLR9 signaling in macrophages and CD3 signaling in T cells induces robust expression of IL-30. J Immunol 2012; 188: 3709-15.
37. Zheng L, Asprodites N, Keene AH, et al. TLR9 engagement on CD4 T lymphocytes represses gamma-radiation-induced apoptosis through activation of checkpoint kinase response elements. Blood 2008; 111: 2704-13.
38. Tedder TF, Poe JC, Fujimoto M, et al. The CD19-CD21 signal transduction complex of B lymphocytes regulates the balance between health and autoimmune disease: systemic sclerosis as a model system. Curr Dir Autoimmun 2005; 8: 55-90.
39. Sato S, Ono N, Steeber DA, et al. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J Immunol 1996; 157: 4371-8.
40. Inaoki M, Sato S, Weintraub BC, et al. CD19-regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes. J Exp Med 1997; 186: 1923-31.
41. Sato S, Hasegawa M, Fujimoto M, et al. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000; 165: 6635-43.
42. Sato S, Fujimoto M, Hasegawa M, et al. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 2004; 41: 1123-33.
43. Rosen A, Casciola-Rosen L. Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. Cell Death Differ 1999; 6: 6-12.
44. Sgonc R, Gruschwitz MS, Dietrich H, et al. Endothelial cell apoptosis is a primary pathogenic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996; 98: 785-92.
45. Ogawa F, Shimizu K, Muroi E, et al. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. Rheumatology (Oxford) 2006; 45: 815-18.
46. Abraham D, Distler O. How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther 2007; 9(Suppl 2): S2.
47. Radic M, Marion T, Monestier M. Nucleosomes are exposed at the cell surface in apoptosis. J Immunol 2004; 172: 6692-700.
48. Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994; 152: 3685-92.
49. Yamamoto T, Nishioka K. Possible role of apoptosis in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 2004; 122: 44-50.
50. Avalos AM, Latz E, Mousseau B, et al. Differential cytokine production and bystander activation of autoreactive B cells in response to CpG-A and CpG-B oligonucleotides. J Immunol 2009; 183: 6262-8.